Renovacor (Renovacor) Accounts Payable : $3.23 Mil (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Renovacor Accounts Payable?

Renovacor's Accounts Payable for the quarter that ended in Sep. 2022 was $3.23 Mil.

Renovacor's quarterly Accounts Payable declined from Mar. 2022 ($1.78 Mil) to Jun. 2022 ($1.55 Mil) but then increased from Jun. 2022 ($1.55 Mil) to Sep. 2022 ($3.23 Mil).

Renovacor's annual Accounts Payable increased from . 20 ($0.00 Mil) to Dec. 2020 ($0.14 Mil) and increased from Dec. 2020 ($0.14 Mil) to Dec. 2021 ($1.54 Mil).

Renovacor Accounts Payable Historical Data

The historical data trend for Renovacor's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor Accounts Payable Chart

Renovacor Annual Data

Trend

Dec20

Dec21

Accounts Payable

0.14

1.54

Renovacor Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Accounts Payable	Get a 7-Day Free Trial				1.50	1.54	1.78	1.55	3.23

Renovacor Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Renovacor Accounts Payable Related Terms

Thank you for viewing the detailed overview of Renovacor's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovacor (Renovacor) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 8142, Greenwich, CT, USA, 06836

Website

https://www.renovacor.com

Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

Executives

Joseph S Carroll	officer: Chief Accounting Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino	director	C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau	director	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr.	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll	officer: Chief Financial Officer
Jonas Grossman	director	17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa	director	17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook	director, officer: Chief Executive Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen	officer: Chief Scientific Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd.	10 percent owner	C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran	officer: Chief Medical Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco	officer: Interim CFO